01 Shift towards Point-of-Care (poc) Devices One key market trend in coagulation testing is the shift towards point-of-care (POC) devices. The demand for portable POC coagulation testing devices is increasing due to the growing preference for home care and decentralized testing solutions. These devices offer faster results, are user-friendly, and reduce the need for frequent hospital visits.The trend is expected to significantly impact market growth as healthcare providers and patients opt for real-time, reliable testing solutions that enhance patient care. Moreover, the integration of advanced technologies like AI and machine learning into diagnostic devices is another emerging market trend. These technologies allow for more accurate and timely diagnosis, which helps healthcare professionals make informed decisions, thereby improving patient outcomes.
02 Top 3 Key Highlights Prothrombin time dominated the test type segment Hospitals dominated the end-user segment North America is the highest shareholder in the global market
01 Rising Prevalence of Coagulation Disorders The increasing prevalence of conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and hemophilia is a key driver of market growth. According to the Centers for Disease Control and Prevention (CDC), DVT affects up to 900,000 people each year in the U.S., with similar patterns seen globally. This rise in coagulation disorders necessitates regular monitoring of blood clotting, leading to a surge in demand for coagulation testing devices. With the development of novel therapeutic agents for these conditions, there is a growing emphasis on early detection and ongoing monitoring, further contributing to the market size.
01 High Cost of Advanced Coagulation Testing The high cost of advanced coagulation testing devices presents a significant barrier to their widespread adoption, particularly in low- to middle-income regions. These devices, equipped with cutting-edge technologies such as automation and integrated diagnostic systems, offer superior accuracy and faster results but come with steep price tags.Additionally, the costs of regular maintenance, calibration, and the need for trained personnel to operate these systems further increase the financial burden on healthcare providers. Smaller clinics and healthcare facilities may struggle to afford these devices, limiting access to advanced testing and hindering market growth, especially in underfunded healthcare sectors globally.
01 Increasing Focus on Personalized Medicine The increasing focus on personalized medicine presents a significant opportunity for the global market. Personalized medicine emphasizes tailoring medical treatments to individual patient profiles, and coagulation testing plays a crucial role in managing patients with clotting disorders.This testing plays a crucial role in this approach, as it helps tailor treatments for patients with clotting disorders, cardiovascular diseases, and cancer. For instance, patients undergoing surgery or those on anticoagulant therapy require individualized coagulation monitoring to adjust medications effectively, which enhances treatment outcomes. Thus, the shift toward personalized treatment plans offers a substantial opportunity for coagulation testing devices that provide real-time, precise data.
September 2025 Sysmex Corporation expanded its coagulation testing solutions by introducing advanced hemostasis technologies and analyzer enhancements designed to improve precision, workflow efficiency, and integration with laboratory information systems.
July 2025 Werfen expanded its Hemostasis business by launching new coagulation assays and software enhancements for its ACL TOP® Family systems, supporting improved clinical decision-making and laboratory productivity.
June 2025 Siemens Healthineers strengthened its hemostasis testing portfolio through advancements in coagulation analyzers and assay technologies. The company focused on improving laboratory automation, standardization, and high-throughput coagulation testing.
May 2025 Roche expanded its coagulation diagnostics portfolio by introducing enhanced automation and workflow capabilities for its coagulation analyzers, enabling clinical laboratories to improve testing efficiency, turnaround time, and diagnostic accuracy.